Intelligence Profile
Research Papers
Research on dihexa, an angiotensin IV analog, is primarily based on preclinical animal studies, with no clinical trials identified in humans to date.
Neurological Applications
The most substantial research focuses on dihexa's potential in treating neurodegenerative conditions. A 2021 study published in Brain Sciences examined dihexa's effects in APP/PS1 mice, a model of Alzheimer's disease. The researchers found that dihexa appeared to rescue cognitive impairment and recover memory function, potentially working through the PI3K/AKT signaling pathway.
Another 2024 study in the Journal of Huntington's Disease investigated dihexa's effects on Huntington's disease-like symptoms in rats induced by 3-nitropropionic acid. A 2018 systematic review in Neuroscience and Biobehavioral Reviews provided a broader analysis of cognitive benefits from angiotensin IV and related compounds like angiotensin-(1-7) across multiple experimental studies.
Other Research Areas
A 2021 study published in Annals of Medicine and Surgery explored dihexa's potential in peripheral nerve repair, examining its use alone or in combination with stem cells and granulocyte-colony stimulating factor in a rat sciatic nerve damage model.
Several studies from 2015-2022 investigated dihexa's role in stem cell research, particularly in directing the differentiation of human pluripotent stem cells into hepatocyte-like cells using small-molecule approaches.
Research Limitations
The available evidence consists entirely of animal studies and in vitro research. Sample sizes and detailed study designs were not provided in the abstracts available. No human clinical trials have been conducted, representing a significant gap between preclinical findings and potential therapeutic applications. The lack of human data means the safety and efficacy of dihexa in people remains unknown.
This information is for educational purposes only and does not constitute medical advice. Consult healthcare professionals for medical decisions.